Company Overview of Liventa Bioscience
AFCell Medical, Inc. produces and supplies amniotic membrane-based biomaterial technology solutions. The company offers amnion, as well as other birth tissue products, such as chorion and amniotic fluids. It also provides AmnioClear, a human allograft membrane transplant for surgical use and to be placed over damaged internal membranes. The company was formerly known as PearlDiver Technologies, Inc. and changed its name to AFCell Medical, Inc. in September 2011. AFCell Medical, Inc. was founded in 2006 and is based in Parsippany, New Jersey.
322 Route 46W
Parsippany, NJ 07054
Founded in 2006
Key Executives for Liventa Bioscience
Founder and Chief Executive Officer
Compensation as of Fiscal Year 2014.
Liventa Bioscience Key Developments
MiMedx Group Announces Update on Outstanding Patent Litigation Filed in the Spring
Oct 21 14
MiMedx Group announced an update on outstanding patent litigation filed in the spring. The company uses human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare. MiMedx has repeatedly stated that it will vigorously defend and enforce its patent portfolio against infringement by third parties.To that end, MiMedx filed two separate patent infringement lawsuits, including an action pending in the Northern District of Georgia against Musculoskeletal Transplant Foundation, Liventa and Medline and another action pending in the Western District of Texas against Bone Bank, et al. Both lawsuits are in the "discovery phase" and "claim construction phase." During the discovery phase, the parties gather from each other and third parties information about the facts and issues in the case. While in the claim construction phase, the Court will engage in a determination of the meaning of the metes and bounds of certain claim terms in dispute between the parties. As expected, the defendants are alleging that their respective products do not infringe MiMedx's patents and/or that the company's patents are invalid, the company said in a release. A defendant seeking to invalidate a patent claim as a defense to a lawsuit must prove invalidity by "clear and convincing evidence." This is a higher evidentiary standard than what a plaintiff, such as MiMedx, has to meet in order to prove infringement, it said. To avoid this higher standard, many defendants are attempting to challenge the validity of a plaintiff's patent claims outside of court through a more recent process known as "inter partes review".
MiMedx Group Files Lawsuit Against Liventa, Medline, And Musculoskeletal Transplant Foundation
Apr 22 14
MiMedx Group, Inc. announced that it has filed a patent infringement lawsuit against Liventa Bioscience, Inc., Medline Industries, Inc. and Musculoskeletal Transplant Foundation, Inc. for permanent injunctive relief and unspecified damages. In addition to the allegations of infringement of MiMedx's patents, the lawsuit asserts that Liventa and Medline knowingly and willfully made false and misleading representations about their respective products to providers, patients and in some cases, prospective investors. The suit was filed in the United States District Court for the Northern District of Georgia. In the suit, MiMedx asserts that Liventa, Medline and MTF infringed and continue to infringe at least four MiMedx patents: US 8,323,701 -- Placental Tissue Grafts, US 8,642,092 -- Placental Tissue Grafts, US 8,372,437 - Placental Tissue Grafts and US 8,597,687 -- Methods for Determining the Orientation of a Placental Tissue Graft. The patents at issue relate to the MiMedx dehydrated human amnion/chorion membrane allografts. MTF is the processor and Liventa and Medline are the distributors of the allegedly infringing products.
AFCell Medical, Inc. has Changed its Name to Liventa Bioscience
Feb 6 14
AFCell Medical, Inc. changed its name to Liventa Bioscience.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 24, 2014